[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583599":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":47,"locations":58,"responsibleParty":118,"collaborators":120,"id":124,"slug":125,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":126,"sex":132,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":42,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":61,"whyStopped":42,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"CBD (Cannabidiol)","EXPERIMENTAL","Each capsule contains a concentration of 50 mg of Cannabidiol (CBD). Participants will receive CBD for a total duration of 8 weeks.",[13],"Drug: CBD",{"label":15,"type":10,"description":16,"interventionNames":17},"THC (∆9-tetrahydrocannabinol)","Each capsule contains a concentration of 3 mg of ∆9-tetrahydrocannabinol (THC). Participants will receive THC capsules for a total duration of 8 weeks.",[18],"Drug: THC",{"label":20,"type":21,"description":22,"interventionNames":23},"Placebo","PLACEBO_COMPARATOR","Participants will receive matching placebo capsules for a total duration of 8 weeks.",[24],"Drug: Placebo",[26,33,39],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","CBD","The starting dose will be 1 capsule per day (50 mg CBD) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (250 mg CBD) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.",[9],[32],"AVCN319301a",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"THC","The starting dose will be 1 capsule per day (3 mg THC) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (15 mg THC) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.",[15],[38],"AVCN319301b",{"type":27,"name":20,"description":40,"armGroupLabels":41,"otherNames":42},"The starting dose will be 1 capsule per day taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.",[20],null,[44],{"name":45,"affiliation":5,"role":46},"Dr. Hance Clarke, MD","PRINCIPAL_INVESTIGATOR",[48,54],{"name":49,"role":50,"phone":51,"phoneExt":52,"email":53},"Sonal Thaker","CONTACT","1-416-340-4800","4251","sonalben.thaker@uhn.ca",{"name":55,"role":50,"phone":51,"phoneExt":56,"email":57},"Deep Grewal","4221","Deep.Grewal@uhn.ca",[59,83,96],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"University Health Network","RECRUITING","Toronto","Ontario","M5G 2C4","Canada","CA",{"type":68,"coordinates":69},"Point",[70,71],-79.39864,43.70643,{"lat":71,"lon":70},[74,79,82],{"name":75,"role":50,"phone":76,"phoneExt":77,"email":78},"Mary Nasim","1-416-603-5800","2932","Mary.nasim@uhn.ca",{"name":80,"role":81,"phone":42,"phoneExt":42,"email":42},"Dr. Timothy Leroux, MD","SUB_INVESTIGATOR",{"name":45,"role":46,"phone":42,"phoneExt":42,"email":42},{"facility":84,"status":61,"city":62,"state":63,"zip":85,"country":65,"countryCode":66,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"Women's College Hospital","M5S 1B2",{"type":68,"coordinates":87},[70,71],{"lat":71,"lon":70},[90,94],{"name":91,"role":50,"phone":92,"phoneExt":42,"email":93},"Didem Bozak","1-(416)-323-6008","Didem.Bozak@wchospital.ca",{"name":95,"role":46,"phone":42,"phoneExt":42,"email":42},"Dr. Karim Ladha, MD",{"facility":97,"status":61,"city":98,"state":99,"zip":100,"country":65,"countryCode":66,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"McGill University Health Centre\u002FMontreal General Hospital","Montreal","Quebec","H3G 1A4",{"type":68,"coordinates":102},[103,104],-73.58781,45.50884,{"lat":104,"lon":103},[107,112,116],{"name":108,"role":50,"phone":109,"phoneExt":110,"email":111},"Karen Smith","1-514-934-1934","43040","karen.smith@muhc.mcgill.ca",{"name":113,"role":50,"phone":109,"phoneExt":114,"email":115},"Tanya Capolicchio","44300","tanya.capolicchio@rimuhc.ca",{"name":117,"role":46,"phone":42,"phoneExt":42,"email":42},"Dr. Mary-Ann Fitzcharles, MD",{"type":119,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[121],{"name":122,"class":123},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV","100583599","cannabinoids-for-osteoarthritis-pain-effectiveness-trial-100583599",false,"NCT06878417","Cannabinoids for Osteoarthritis Pain Effectiveness Trial","The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: an Internal Pilot, Placebo Controlled, Blinded Randomized Trial","COPE","Inclusion Criteria:\n\n1. Age 40-80 years\n2. Diagnosed with hip and\u002For knee osteoarthritis as per the American College of Rheumatology criteria\n3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60\n4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks\n5. Able to self-report, understand and read English or French\n\nExclusion Criteria:\n\n1. Hip or knee surgery planned in the coming 4 months,\n2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.),\n3. Planned injection into the affected joint(s) during trial period,\n4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.),\n5. Contraindications to taking cannabis\u002Fcannabinoids,\n6. Used nabilone or nabiximols in the last 30 days,\n7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout),\n8. A history of diagnosed cannabis use disorder or dependence,\n9. Active substance use disorder,\n10. Current DSM-V diagnosis of bipolar disorder, major depression, or psychosis,\n11. An uncontrolled medical or major psychiatric disorder,\n12. Currently on warfarin,\n13. Known pregnancy or currently breastfeeding,\n14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs\n15. No fixed address or a plan to change addresses in the coming 4 months,\n16. Known or suspected allergy to palm\u002Fcoconut oil","ALL","40 Years","80 Years",{"count":136,"type":137},100,"ESTIMATED","INTERVENTIONAL",[140],"NA","This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy.\n\nThe goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and\u002For knee osteoarthritis.\n\nParticipants will:\n\n* Take either CBD, THC, or a placebo capsule daily for 8 weeks\n* Complete follow-ups remotely, with no in-person clinic visits required\n* Maintain a diary tracking their study drug usage and any additional pain medications",[143,144],"Osteoarthritis of Knee","Osteoarthritis Hip",[146],"Medical Cannabis","2026-06-17",{"date":149,"type":150},"2026-06-22","ACTUAL",{"date":152,"type":150},"2026-01-29",{"date":154,"type":137},"2027-02-28",{"name":5,"class":6},3]